Burning Rock Biotech Limited 3Q 2025 results 20 November 2025 Disclaimer This presentation has been prepared by Burning Rock Biotech Limited (the "Company") solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions present ...

Core Insights - Burning Rock Biotech Limited reported a total revenue of RMB 131.6 million (US$ 18.5 million) for Q3 2025, marking a 2.3% increase from RMB 128.6 million in Q3 2024 [3] - The company achieved a gross profit of RMB 98.8 million (US$ 13.9 million) for the same period, representing a 7.6% increase from RMB 91.8 million in Q3 2024, with a gross margin of 75.1% [5] - The net loss for Q3 2025 was RMB 16.8 million (US$ 2.4 million), a significant improvement compared to a net loss of RMB 35.7 million in Q3 2024 [10] Financial Performance - Total revenues for Q3 2025 were RMB 131.6 million (US$ 18.5 million), up from RMB 128.6 million in Q3 2024 [3] - Cost of revenues decreased to RMB 32.8 million (US$ 4.6 million) in Q3 2025, down 10.9% from RMB 36.8 million in Q3 2024 [4] - Gross profit increased to RMB 98.8 million (US$ 13.9 million) in Q3 2025, with a gross margin of 75.1%, compared to 71.4% in Q3 2024 [5][7] - Non-GAAP gross profit for Q3 2025 was RMB 100.9 million (US$ 14.2 million), a 3.2% increase from RMB 97.8 million in Q3 2024 [8] Revenue Breakdown - Revenue from the in-hospital business was RMB 52.8 million (US$ 7.4 million) in Q3 2025, a 17.1% decrease from RMB 63.8 million in Q3 2024 [6] - Revenue from the central laboratory business was RMB 36.8 million (US$ 5.2 million), down 7.9% from RMB 40.0 million in Q3 2024 [6] - Revenue from pharma research and development services surged to RMB 42.0 million (US$ 5.9 million), a 68.6% increase from RMB 24.9 million in Q3 2024 [6] Operating Expenses - Total operating expenses for Q3 2025 were RMB 115.0 million (US$ 16.2 million), down 11.9% from RMB 130.4 million in Q3 2024 [9] - Research and development expenses decreased to RMB 41.5 million (US$ 5.8 million), a 15.6% decline from RMB 49.2 million in Q3 2024 [13] - Selling and marketing expenses were RMB 41.8 million (US$ 5.9 million), down 13.6% from RMB 48.4 million in Q3 2024 [13] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling RMB 467.0 million (US$ 65.6 million) [10]

Core Viewpoint - Riken Genesis Co., Ltd. and Burning Rock Biotech Limited announced the approval of the OncoGuide™ OncoScreen™ Plus CDx System in Japan, which will serve as a companion diagnostic for AstraZeneca's capivasertib, enhancing precision diagnostics for breast cancer patients [1][4][5]. Group 1: Product Details - The OncoGuide™ OncoScreen™ Plus CDx System is a combination medical device that includes the OncoGuide™ OncoScreen™ Plus CDx Kit and the OncoGuide™ OncoScreen™ Plus CDx Analysis Program, designed for use with next-generation sequencing [3][8]. - This diagnostic tool detects PIK3CA, AKT1, and PTEN alterations in a single test, aimed at guiding treatment decisions for adult patients with unresectable or recurrent hormone-receptor-positive, HER2-negative breast cancer [3][4]. Group 2: Market Impact - The approval of the CDx system is expected to improve access to precision diagnostics for breast cancer patients in Japan, ultimately expanding therapeutic opportunities [4]. - Riken Genesis plans to prepare for insurance coverage to ensure timely and equitable access for all eligible patients [4]. Group 3: Company Insights - Burning Rock's CEO highlighted that the approval is a significant milestone in the company's global strategy, emphasizing the system's role in optimizing treatment plans and enhancing patient outcomes [5]. - Riken Genesis expressed commitment to delivering the innovative diagnostic tool to patients as quickly as possible, marking their first approval for a combination medical device product [5][9].